Comparative Pharmacology
Head-to-head clinical analysis: PROMPT PHENYTOIN SODIUM versus VIGADRONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROMPT PHENYTOIN SODIUM versus VIGADRONE.
PROMPT PHENYTOIN SODIUM vs VIGADRONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenytoin stabilizes neuronal membranes by promoting sodium channel inactivation, thereby reducing repetitive firing of action potentials and inhibiting the spread of seizure activity.
Irreversible inhibitor of GABA transaminase (GABA-T), leading to increased brain concentrations of gamma-aminobutyric acid (GABA).
Loading dose: 15-20 mg/kg (max 1500 mg) IV at a rate not exceeding 50 mg/min. Maintenance dose: 300-600 mg/day IV or orally in 3 divided doses. Adjust per therapeutic drug monitoring (target total phenytoin 10-20 mcg/mL).
Adults: 500 mg orally twice daily, may increase by 500 mg/day every week; maximum 1500 mg twice daily.
None Documented
None Documented
30-100 hours (average 40 hours) following IV administration; prolonged in hepatic impairment, neonates, and with enzyme inhibitors; shorter in children and with enzyme inducers.
Terminal elimination half-life: 5-7 hours in young adults; 12-15 hours in elderly; therapeutic steady-state achieved within 2-3 days.
Primarily hepatic metabolism (CYP2C9) to inactive p-HPPH. Renal excretion as p-HPPH glucuronide (~60-70%) and unchanged drug (5%), with ~30% biliary/fecal elimination.
Renal: 70% unchanged; hepatic metabolism: 20% (primarily via CYP4A7, not CYP450); fecal: <5%.
Category D/X
Category C
Anticonvulsant
Anticonvulsant